DK0807633T3 - Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner - Google Patents
Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-onerInfo
- Publication number
- DK0807633T3 DK0807633T3 DK97303000T DK97303000T DK0807633T3 DK 0807633 T3 DK0807633 T3 DK 0807633T3 DK 97303000 T DK97303000 T DK 97303000T DK 97303000 T DK97303000 T DK 97303000T DK 0807633 T3 DK0807633 T3 DK 0807633T3
- Authority
- DK
- Denmark
- Prior art keywords
- disubstituted
- ones
- heteroaryl condensed
- newly known
- pyrimidin
- Prior art date
Links
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical class O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1773796P | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0807633T3 true DK0807633T3 (da) | 2002-11-25 |
Family
ID=21784263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97303000T DK0807633T3 (da) | 1996-05-15 | 1997-05-01 | Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5962457A (da) |
| EP (1) | EP0807633B1 (da) |
| JP (1) | JP3270360B2 (da) |
| AT (1) | ATE227293T1 (da) |
| CA (1) | CA2205274C (da) |
| DE (1) | DE69716810T2 (da) |
| DK (1) | DK0807633T3 (da) |
| ES (1) | ES2184960T3 (da) |
| PT (1) | PT807633E (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9807807A (pt) * | 1997-02-28 | 2000-02-22 | Pfizer Prod Inc | AtropisÈmeros de 3-heteroaril-4(3h)-quinazolinonas para o tratamento de condições neurodegenerativas e relacionadas com trauma do sistema nervoso central (snc) |
| US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
| JP2002533465A (ja) * | 1998-12-23 | 2002-10-08 | デュポン ファーマシューティカルズ カンパニー | Ｘａ因子阻害剤としての窒素を含む複素二環類 |
| US6858616B2 (en) | 1998-12-23 | 2005-02-22 | Bristol-Myers Squibb Pharma Company | Nitrogen containing heterobicycles as factor Xa inhibitors |
| CA2397493A1 (en) * | 2000-01-27 | 2001-08-02 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US7285557B2 (en) * | 2001-10-15 | 2007-10-23 | Smithkline Beecham P.L.C. | Pyrimidinones as melanin concentrating hormone receptor 1 |
| JP2007511496A (ja) | 2003-11-14 | 2007-05-10 | メルク シャープ エンド ドーム リミテッド | バニロイド−１受容体（ｖｒ１）の機能を調節する二環式ピリミジン−４−（３ｈ）−オン類並びにその類似体及び誘導体 |
| US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
| CN101563349A (zh) * | 2006-08-23 | 2009-10-21 | 神经能质公司 | 经卤烷基取代的嘧啶酮衍生物 |
| WO2008024438A2 (en) * | 2006-08-23 | 2008-02-28 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
| WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| MX2010007419A (es) * | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| MX386085B (es) | 2012-11-01 | 2025-03-18 | Infinity Pharmaceuticals Inc | Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa |
| US9527834B2 (en) | 2013-04-28 | 2016-12-27 | Vanderbilt University | Substituted 1-benzylquinoxalin-2(1H)-one analogs as positive allosteric modulators of muscarinic acetylcholine receptor M1 |
| US9540371B2 (en) | 2013-04-29 | 2017-01-10 | Vanderbilt University | Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1 |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
| HK1255034A1 (zh) | 2015-07-01 | 2019-08-02 | Crinetics Pharmaceuticals, Inc. | 生长抑素调节剂及其用途 |
| CN109311868B (zh) | 2015-12-22 | 2022-04-01 | 尚医治疗有限责任公司 | 用于治疗癌症和炎性疾病的化合物 |
| RU2754507C2 (ru) | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| EP3642209B1 (en) | 2017-06-21 | 2023-11-29 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| NZ790364A (en) | 2020-01-29 | 2025-12-19 | Kamari Pharma Ltd | Compounds and compositions for use in treating skin disorders |
| CN115353514B (zh) * | 2022-08-31 | 2023-07-25 | 河南师范大学 | 氟代吡啶并嘧啶酮类化合物及其合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
| US3748325A (en) * | 1970-04-06 | 1973-07-24 | Karamchand Premchand Private | Process for the preparation of quinazolinone derivatives |
| BE769844A (en) * | 1970-07-14 | 1972-01-12 | Ucb Sa | Thieno(3,4-d)-4-pyrimidones - having cardiovascular, analgesic, antiinflammatory, cytostatic,bacteriostatic, fungistatic, and cns -st |
| WO1989008113A1 (en) * | 1988-03-02 | 1989-09-08 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF |
| US5268378A (en) * | 1990-05-31 | 1993-12-07 | Merck Sharp & Dohme, Limited | Dioxo-tetrahydroquinoline derivatives |
| GB9026389D0 (en) * | 1990-12-05 | 1991-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
| GB9125485D0 (en) * | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9206266D0 (en) * | 1992-03-23 | 1992-05-06 | Merck Sharp & Dohme | Therapeutic agents |
| US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
-
1997
- 1997-05-01 AT AT97303000T patent/ATE227293T1/de not_active IP Right Cessation
- 1997-05-01 DE DE69716810T patent/DE69716810T2/de not_active Expired - Fee Related
- 1997-05-01 ES ES97303000T patent/ES2184960T3/es not_active Expired - Lifetime
- 1997-05-01 DK DK97303000T patent/DK0807633T3/da active
- 1997-05-01 EP EP97303000A patent/EP0807633B1/en not_active Expired - Lifetime
- 1997-05-01 PT PT97303000T patent/PT807633E/pt unknown
- 1997-05-13 CA CA002205274A patent/CA2205274C/en not_active Expired - Fee Related
- 1997-05-14 US US08/855,630 patent/US5962457A/en not_active Expired - Fee Related
- 1997-05-15 JP JP12595397A patent/JP3270360B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE227293T1 (de) | 2002-11-15 |
| JPH1045757A (ja) | 1998-02-17 |
| DE69716810D1 (de) | 2002-12-12 |
| DE69716810T2 (de) | 2003-02-27 |
| MX9703610A (es) | 1998-06-30 |
| CA2205274A1 (en) | 1997-11-15 |
| JP3270360B2 (ja) | 2002-04-02 |
| EP0807633B1 (en) | 2002-11-06 |
| ES2184960T3 (es) | 2003-04-16 |
| EP0807633A2 (en) | 1997-11-19 |
| PT807633E (pt) | 2003-02-28 |
| US5962457A (en) | 1999-10-05 |
| EP0807633A3 (en) | 1998-05-13 |
| CA2205274C (en) | 2003-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0807633T3 (da) | Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner | |
| EA200000592A1 (ru) | Азаполициклические соединения, конденсированные с арилом | |
| ES2149761T3 (es) | Derivado de piridazinona. | |
| BG102999A (bg) | Нови 2,3 дизаместени-4(3н)-хиназолинони | |
| DE69705300D1 (de) | Cyclopropylalkansäurederivate | |
| CA2258548A1 (en) | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases | |
| ATE212978T1 (de) | Para-substituierte phenylpropansäure derivate als integrin-antagonisten | |
| NO178969C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte kinazolinoner | |
| ATE203515T1 (de) | Meta-substituierte phenylsulphonamidderivate | |
| DE3481841D1 (de) | Bicyclische kondensierte n-(4-piperidinyl)-2-imidazolamin-derivate. | |
| DK0894084T3 (da) | Kanelsyrederivater og deres anvendelse som integrinantagonister | |
| PT896533E (pt) | Pentafluorobenzenosulfonamidas e analogos | |
| FI101376B1 (fi) | Menetelmä 3-bentsyyliamino-2-fenyylipiperidiinijohdannaisten valmistamiseksi | |
| ATE211729T1 (de) | Therapeutisch wirksame verbindungen | |
| EA200100516A1 (ru) | Производные 3,3-биарилпиперидина и 2,2-биарилморфолина | |
| PT992509E (pt) | Novos derivados macrolidos | |
| DE69917717D1 (de) | C11-Carbamate von antibakteriellen Makroliden | |
| EA200000741A1 (ru) | Новые производные дигидроксигексановой кислоты | |
| DE69613457D1 (de) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansäure derivate als tachykinin rezeptor antagonisten | |
| MD1560F2 (en) | Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses. | |
| EA200000996A1 (ru) | Конденсированные с арилом азаполициклические соединения | |
| BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
| NO159927C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive aromatiske aminoacetylener. | |
| NO842345L (no) | Heksahydropyrrolo(2,1-a)isoquinolin-derivater. | |
| DE69827706D1 (de) | 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems |